Kelvin Alexander Moses, MD, PhD, discusses recent trials in metastatic hormone-sensitive prostate cancer.
Kelvin Alexander Moses, MD, PhD, associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses recent trials in metastatic hormone-sensitive prostate cancer (mHSPC).
The phase III CHAARTED trial established the use of chemotherapy in combination with androgen deprivation therapy (ADT) over ADT alone after showing an improvement in median overall survival (OS). At 53.7 months, the median OS with the combination was 57.6 months versus 47.2 months with ADT alone.
Additionally, a subgroup analysis showed that patients with high-volume disease, either visceral metastasis or >4 bone lesions including 1 lesion outside the axial skeleton, derived greater benefit from the combination. In this subgroup, median OS was 51.2 months with the combination versus 34.4 months with ADT alone.
Furthermore, in 2019, the final analysis of the phase III LATITUDE trial demonstrated a significant improvement in median OS with abiraterone acetate (Zytiga) in combination with prednisone, ADT, and placebo compared with ADT plus placebo, says Moses. Specifically, median OS was 53.3 months with the combination versus 36.5 months with ADT alone. In February 2018, abiraterone acetate in combination with prednisone was approved for use in patients with metastatic high-risk metastatic, castration-sensitive prostate cancer based on the LATITUDE data.